Treatment of pulmonary hypertension: bench to bedside

Springer, J, Lainscak, M, Salobir, B and Lang, IM (2011) Treatment of pulmonary hypertension: bench to bedside. Respiratory Medicine, 105 Suppl 1. S7-11. ISSN 0954-6111

Full text not available from this repository.


Pulmonary arterial hypertension is an orphan disease and a model for drug developments over recent years. Expert centers have focused basic science on the pulmonary vasculature and the right ventricle, followed by a direct transfer of innovative concepts to clinical research. Successful examples for translational experimentation are the endothelin receptor antagonists, prostacyclin receptor agonists, and the activators of soluble guanylate cyclase. On the other hand, there have been failures such as vasoactive intestinal peptide, statins, and escitalopram. Several new drugs and gene therapy are under investigation, thus significant advances are anticipated.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
University of East Anglia > Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User: Jochen Springer
Date Deposited: 29 Apr 2013 14:00
Last Modified: 29 Aug 2018 10:30

Actions (login required)

View Item